The program will initially target blindness therapy Luxturna and Zolgensma, a spinal treatment drug and the world's most expensive rare disease drug. (Photo: Shutterstock)
Insurance giant Cigna has made the latest move in the elaborate chess match being played out over who will pay for life-saving rare disease therapies.
In a release, the company–which owns Express Scripts, one of the most powerful pharmacy benefit managers–said it has created a solution that will allow patients to access the drugs they need at no cost to them. "Those who provide health coverage for millions of Americans, such as employers, health plans and unions, will have the peace of mind that comes from being better protected against the high price shocks associated with new breakthrough therapies," the company wrote in a statement.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Dan Cook
Dan Cook is a journalist and communications consultant based in Portland, OR. During his journalism career he has been a reporter and editor for a variety of media companies, including American Lawyer Media, BusinessWeek, Newhouse Newspapers, Knight-Ridder, Time Inc., and Reuters. He specializes in health care and insurance related coverage for BenefitsPRO.
